These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35868481)

  • 21. Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19.
    Gyanwali P; Sharma S; Pant S; Koirala P; Adhikari K; Koirala J; Dhimal M
    J Nepal Health Res Counc; 2020 Sep; 18(2):151-158. PubMed ID: 32969369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gallium Components-Based Drug Delivery: A Potential Treatment for COVID-19.
    Torabi S; Bahreini F; Rezaei N
    Infect Disord Drug Targets; 2022; 22(3):e270122200590. PubMed ID: 35086461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
    Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
    Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19: Potential Repurposing Drugs.
    Leowattana W
    Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanotechnology-based Approaches and Investigational Therapeutics against COVID-19.
    Rahman MM; Ahmed M; Islam MT; Khan MR; Sultana S; Maeesa SK; Hasan S; Hossain MA; Ferdous KS; Mathew B; Rauf A; Uddin MS
    Curr Pharm Des; 2022; 28(12):948-968. PubMed ID: 34218774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current therapies under investigation for COVID-19: potential COVID-19 treatments.
    Weisberg E; Sattler M; Yang PL; Parent A; Gray N; Griffin JD
    Can J Physiol Pharmacol; 2020 Aug; 98(8):483-489. PubMed ID: 32640179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
    Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
    Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].
    Javelot H; Llorca PM; Drapier D; Fakra E; Hingray C; Meyer G; Dizet S; Egron A; Straczek C; Roser M; Masson M; Gaillard R; Fossati P; Haffen E
    Encephale; 2020 Jun; 46(3S):S14-S34. PubMed ID: 32376004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
    Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
    FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
    Bai Y; Shen M; Zhang L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential Prophylactic Treatments for COVID-19.
    Ben-Zuk N; Dechtman ID; Henn I; Weiss L; Afriat A; Krasner E; Gal Y
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
    Krishna G; Pillai VS; Veettil MV
    Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
    Dhankhar P; Dalal V; Kumar V
    J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19.
    Khanna K; Raymond WW; Jin J; Charbit AR; Gitlin I; Tang M; Werts AD; Barrett EG; Cox JM; Birch SM; Martinelli R; Sperber HS; Franz S; Duff T; Hoffmann M; Healy AM; Oscarson S; Pöhlmann S; Pillai SK; Simmons G; Fahy JV
    Am J Physiol Lung Cell Mol Physiol; 2022 Sep; 323(3):L372-L389. PubMed ID: 35762590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID19- clinical presentation and therapeutic considerations.
    Kenny G; Mallon PW
    Biochem Biophys Res Commun; 2021 Jan; 538():125-131. PubMed ID: 33218685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic targets and potential agents for the treatment of COVID-19.
    Wu Y; Li Z; Zhao YS; Huang YY; Jiang MY; Luo HB
    Med Res Rev; 2021 May; 41(3):1775-1797. PubMed ID: 33393116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.
    Reiter RJ; Sharma R; Simko F; Dominguez-Rodriguez A; Tesarik J; Neel RL; Slominski AT; Kleszczynski K; Martin-Gimenez VM; Manucha W; Cardinali DP
    Cell Mol Life Sci; 2022 Feb; 79(3):143. PubMed ID: 35187603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.
    Vandyck K; Deval J
    Curr Opin Virol; 2021 Aug; 49():36-40. PubMed ID: 34029993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
    de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
    Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.